/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

C

Caroline Mollévi

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

243

Papers

6.7K

Citations

41

h-index

95

i10-index

Caroline Mollévi is an academic researcher from Inserm. The author has contributed to research in topics: Colorectal Cancer Treatments and Studies & Health Systems, Economic Evaluations, Quality of Life & Cancer Genomics and Diagnostics. The author has an h-index of 41, co-authored 207 publications.

ORCID: 0000-0003-4827-3684

Research Topics

Colorectal Cancer Treatments and Studies Health Systems, Economic Evaluations, Quality of Life Cancer Genomics and Diagnostics Cancer survivorship and care Monoclonal and Polyclonal Antibodies Research

Papers by this author

works

Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database

2011 · Journal of Clinical Oncology · 263 citations

https://doi.org/10.1200/jco.2010.32.6678

Anja Lorch Caroline Mollévi Andrew Kramar Lawrence Einhorn

Distribution- and anchor-based methods to determine the minimally important difference on patient-reported outcome questionnaires in oncology: a structured review

2018 · Health and Quality of Life Outcomes · 148 citations

https://doi.org/10.1186/s12955-018-1055-z

Ahmad Ousmen Célia Touraine Nina Deliu Francesco Cottone

Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?

2013 · Quality of Life Research · 125 citations

https://doi.org/10.1007/s11136-013-0583-6

Amélie Anota Zeinab Hamidou Sophie Paget‐Bailly Benoist Chibaudel

Inhibition of <scp>DDR</scp> 1‐ <scp>BCR</scp> signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer

2018 · EMBO Molecular Medicine · 109 citations

https://doi.org/10.15252/emmm.201707918

Maya Jeitany Cédric Leroy Priscillia Tosti M. Lafitte

Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPY”phase 1-2 trial

2015 · Oncotarget · 83 citations

https://doi.org/10.18632/oncotarget.3473

Eric Assénat D. Azria Caroline Mollévi Rosine Guimbaud

Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers

2018 · British Journal of Cancer · 76 citations

https://doi.org/10.1038/s41416-018-0142-6

Séverine Guiu Caroline Mollévi Céline Charon‐Barra Florence Boissière‐Michot

Research topics

topics

Colorectal Cancer Treatments and Studies

Health Systems, Economic Evaluations, Quality of Life

Cancer Genomics and Diagnostics

Cancer survivorship and care

Monoclonal and Polyclonal Antibodies Research

Chat about Author

Papers

Chat

Click to start Chat